Lv73
5020 积分 2023-08-18 加入
When Shorter Is Sweeter: Early Discontinuation of Immune Checkpoint Inhibitors in Advanced NSCLC
5天前
已关闭
Beyond PACIFIC: Rethinking Consolidation in Molecularly Defined Stage III NSCLC
5天前
已关闭
Ivonescimab in advanced squamous non-small-cell lung cancer: can we raise the survival bar?
8天前
已完结
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
10天前
已完结
Reducing bias in healthcare artificial intelligence: A white paper
1个月前
已关闭
The generative era of medical AI
1个月前
已关闭
The Expanding Landscape of Next-Generation EGFR Tyrosine Kinase Inhibitors: Have We Reached Capacity?
2个月前
已完结
Priming for Cure: How Perioperative Immunotherapy Is Redrawing Surgical Boundaries
2个月前
已完结
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 “DICIPLE” Phase III Trial
2个月前
已完结
Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
